Bradley Foster & Sargent Inc Alnylam Pharmaceuticals, Inc. Transaction History

Bradley Foster & Sargent Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Mar 11, 2022	SELL	$159.56 - $209.29 $833,381 - $1.09 Million	-5,223 Closed	0 $0
Q2 2021 Aug 19, 2021	SELL	$128.63 - $176.89 $208,637 - $286,915	-1,622 Reduced 23.7%	5,223 $885,000
Q1 2021 Apr 26, 2021	SELL	$126.83 - $175.69 $437,943 - $606,657	-3,453 Reduced 33.53%	6,845 $966,000
Q4 2020 Feb 11, 2021	BUY	$122.97 - $147.0 $1.27 Million - $1.51 Million	10,298 New	10,298 $1.34 Million
Q3 2018 Oct 31, 2018	SELL	$87.52 - $122.67 $277,876 - $389,477	-3,175 Closed	0 $0
Q2 2018 Jul 31, 2018	SELL	$88.31 - $107.8 $187,217 - $228,536	-2,120 Reduced 40.04%	3,175 $313,000
Q1 2018 May 07, 2018	SELL	$115.92 - $148.54 $340,804 - $436,707	-2,940 Reduced 35.7%	5,295 $631,000
Q3 2017 Nov 03, 2017	BUY	$72.53 - $118.27 $597,284 - $973,953	8,235	8,235 $968,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Bradley Foster & Sargent Inc, based on Form 13F filings with the SEC.

Stay updated on Bradley Foster & Sargent Inc with notifications on news.